Patents by Inventor Masahito SHIMOJO

Masahito SHIMOJO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING
    Publication number: 20240148775
    Abstract: An oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention contains a nucleotide sequence complementary to a continuous sequence of at least 12 bases in a target region constituted by a base sequence of SEQ ID No. 1, and induces N-exon skipping in human REST pre-mRNA processing. Such oligonucleotides are useful for manufacturing medicines for treatment of cancer, for example.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 9, 2024
    Applicant: Osaka University
    Inventors: Masahito SHIMOJO, Satoshi OBIKA, Keishiro MISHIMA, Misa YOSHIDA
  • Small cell lung cancer therapeutic agent containing oligonucleotide
    Patent number: 11866705
    Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 9, 2024
    Assignees: Osaka Univerity, National Institutes of Biomedical Innovation, Health and Nutrition, Luxna Biotech Co., Ltd.
    Inventors: Masahito Shimojo, Satoshi Obika, Yuya Kasahara, Takao Suzuki, Masaki Yamagami, Tadashi Umemoto
  • SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE
    Publication number: 20210277398
    Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: September 9, 2021
    Inventors: Masahito SHIMOJO, Satoshi OBIKA, Yuya KASAHARA, Takao SUZUKI, Masaki YAMAGAMI, Tadashi UMEMOTO